CC BY 4.0 · TH Open 2018; 02(03): e325-e328
DOI: 10.1055/s-0038-1672186
Original Article
Georg Thieme Verlag KG Stuttgart · New York

An Assessment of the Effectiveness of Warfarin Therapy Monitoring Systems on Thrombophilic Patients in Zimbabwe

Aaron Maramba
1   Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
,
Silenkosi Ncube
1   Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
,
Arthur Mandisodza
1   Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
,
Dayana Da Silva Marques
2   Department of Haematology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
,
Tsehay Matsikure
3   Department of Haematology, National Public Health Laboratories, Parirenyatwa Group of Hospitals, Harare, Zimbabwe
› Institutsangaben
Weitere Informationen

Publikationsverlauf

08. Juni 2018

08. August 2018

Publikationsdatum:
26. September 2018 (online)

Abstract

Introduction Thrombophilia describes conditions that predispose individuals to increased blood clotting and includes conditions such as deep vein thrombosis and pulmonary embolism. Thrombophilia is associated with high morbidity and mortality rates, and is commonly treated by warfarin anticoagulation. However, warfarin may cause both bleeding and clotting episodes if the therapy is not monitored and managed effectively.

Objectives The main objective of this study was to assess the effectiveness of warfarin monitoring systems on thrombophilic patients at a major hospital in Zimbabwe.

Material and Methods A clinical and laboratory prospective and retrospective study was performed on patients who had been on warfarin therapy for at least 1 year. Questionnaires were administered to participants on warfarin from outpatients clinics at Parirenyatwa Group of Hospitals. Their international normalized ratio (INR) results were also accessed from the laboratory information system and captured in the Epi info and Microsoft Excel for analysis.

Results Fifty questionnaires were administered and 47 (94%) participants responded adequately. Twenty-nine (61.1%) participants on warfarin were females. The majority of them were elderly and in the 31 to 40 age groups. Eighteen (38.3%) participants missed their medication at some point, while 12 (25.5%) had warfarin overdose. Sixteen (34%) and 11 (23.4%) admitted to taking alcohol and smoking, respectively, while on warfarin. Thirty-five (74.5%) did not change their medication nor were advised on the right diet. Thirty-four (72.3%) had appointments set after every month. Some participants indicated that they had symptoms of both clotting and bleeding. There were statistically significant differences (p < 0.0001) between INRs for 3 monthly intervals from the initiation of warfarin therapy.

Conclusion Women and the elderly formed the majority of the patients on warfarin, indicating gender and advanced age susceptibility to thrombophilia, respectively. The effectiveness of the warfarin monitoring systems appeared to be hampered by lack of a coordinated system that adequately monitors anticoagulant therapy in the country.

 
  • References

  • 1 Hoffbrand AV, Moss PAH. Thrombosis 2: treatment. In: Hoffbrand AV, Moss PAH. , eds. Hoffbrand's Essential Haematology. 7th ed. Oxford, UK: Wiley Blackwell; 2016: 311-320
  • 2 Kakkos SK, Griffin M, Geroulakos G, Nicolaides AN. The efficacy of a new portable sequential compression device (SCD Express) in preventing venous stasis. J Vasc Surg 2005; 42 (02) 296-303
  • 3 Spychalska-Zwolińska M, Zwoliński T, Mieczkowski A, Budzyński J. Thrombophilia diagnosis: a retrospective analysis of a single-center experience. Blood Coagul Fibrinolysis 2015; 26 (06) 649-654
  • 4 Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99 (09) 3102-3110
  • 5 Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med 1998; 158 (5, Pt 1): 1369-1373
  • 6 Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 2004; 109 (12) (Suppl. 01) I4-I8
  • 7 Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001; 114 (02) 271-280
  • 8 Hirsh J, Dalen J, Anderson DR. , et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1, Suppl): 8S-21S
  • 9 Poller L, Keown M, Ibrahim S. , et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6 (06) 935-943
  • 10 Weingarz L, Schwonberg J, Schindewolf M. , et al. Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. Br J Haematol 2013; 163 (05) 655-665
  • 11 Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126 (04) 557-564
  • 12 Kimmel SE, Chen Z, Price M. , et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167 (03) 229-235
  • 13 Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodting T, Piriyachananusorn N. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 2011; 139 (05) 1130-1139
  • 14 Noureldin M, Krause J, Jin L, Ng V. Drug-alcohol interactions: a review of three therapeutic classes. US Pharm 2010; 35 (11) 29-40
  • 15 Ministry of Health and Child Care Team. Anticoagulation. Essential Medicines List and Standard Treatment Guidelines for Zimbabwe (EDLIZ). 7th ed. Harare, Zimbabwe: The Ministry of Health and Child Care; 2015:332–333
  • 16 Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44 (02) 62-69